Trial Outcomes & Findings for EXPLORER PET/CT in Healthy Volunteers (NCT NCT04110743)
NCT ID: NCT04110743
Last Updated: 2024-11-21
Results Overview
To collect preliminary data regarding FDG biodistribution in the organs listed as a function of time of 12 hours. Time-activity curves will be created
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
30 participants
Primary outcome timeframe
approximatively 12 hours for Arm 1 only
Results posted on
2024-11-21
Participant Flow
Participant milestones
| Measure |
Delayed Imaging Acquisition
10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Low FDG Dose Imaging
0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Comparison PET Images Reconstructed Using CT-based Attenuation
10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
|---|---|---|---|
|
Overall Study
STARTED
|
15
|
15
|
0
|
|
Overall Study
COMPLETED
|
15
|
15
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
EXPLORER PET/CT in Healthy Volunteers
Baseline characteristics by cohort
| Measure |
Delayed Imaging Acquisition
n=15 Participants
10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Low FDG Dose Imaging
n=15 Participants
0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Comparison PET Images Reconstructed Using CT-based Attenuation
10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Total
n=30 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
0 Participants
n=7 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
14 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
—
|
29 Participants
n=7 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
1 Participants
n=7 Participants
|
|
Age, Continuous
|
49.5 YEARS
n=99 Participants
|
45.3 YEARS
n=107 Participants
|
—
|
47.4 YEARS
n=7 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
—
|
16 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
—
|
14 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
15 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
—
|
30 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
—
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
—
|
17 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
—
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
8 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
—
|
12 Participants
n=7 Participants
|
|
Region of Enrollment
United States
|
15 participants
n=99 Participants
|
15 participants
n=107 Participants
|
—
|
30 participants
n=7 Participants
|
PRIMARY outcome
Timeframe: approximatively 12 hours for Arm 1 onlyTo collect preliminary data regarding FDG biodistribution in the organs listed as a function of time of 12 hours. Time-activity curves will be created
Outcome measures
| Measure |
Delayed Imaging Acquisition
n=15 Participants
10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Arm 2
Average SUV mean at 90 minutes
|
|---|---|---|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Aorta
|
0.83 SUV
Standard Deviation 0.47
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Lungs
|
0.48 SUV
Standard Deviation 0.44
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Liver
|
1.68 SUV
Standard Deviation 0.51
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Spleen
|
2.01 SUV
Standard Deviation 0.49
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Kidneys
|
1.91 SUV
Standard Deviation 0.83
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Bone Marrow
|
3.44 SUV
Standard Deviation 0.85
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Skeletal Muscles
|
1.23 SUV
Standard Deviation 0.44
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Subcutaneous Fat
|
0.25 SUV
Standard Deviation 0.21
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Whole Brain
|
5.81 SUV
Standard Deviation 1.87
|
—
|
|
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UM
Myocardium
|
14.0 SUV
Standard Deviation 6.93
|
—
|
PRIMARY outcome
Timeframe: approximatively 6 hours for Arm 1 onlyTo obtain preliminary data regarding low dose EXPLORER noise level
Outcome measures
| Measure |
Delayed Imaging Acquisition
n=15 Participants
10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Arm 2
Average SUV mean at 90 minutes
|
|---|---|---|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Aorta
|
60.5 coefficient
Standard Deviation 14.8
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Lungs
|
140.1 coefficient
Standard Deviation 8.1
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Liver
|
32.2 coefficient
Standard Deviation 9.0
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Spleen
|
31.4 coefficient
Standard Deviation 9.3
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Kidneys
|
64.4 coefficient
Standard Deviation 18.4
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Bone Marrow
|
40.8 coefficient
Standard Deviation 11.8
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Skeletal Muscles
|
53.0 coefficient
Standard Deviation 18.8
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Subcutaneous Fat
|
88.6 coefficient
Standard Deviation 24.8
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Whole Brain
|
54.5 coefficient
Standard Deviation 8.1
|
—
|
|
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)
Myocardium
|
63.0 coefficient
Standard Deviation 16.7
|
—
|
PRIMARY outcome
Timeframe: approximatively 90 minutesTo collect preliminary data about total body FDG perfusion and early biodistribution. Time-activity curves will be created
Outcome measures
| Measure |
Delayed Imaging Acquisition
n=15 Participants
10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Arm 2
n=15 Participants
Average SUV mean at 90 minutes
|
|---|---|---|
|
Standardized Uptake Value
Lungs
|
0.62 SUV
Standard Deviation 0.37
|
0.32 SUV
Standard Deviation 0.06
|
|
Standardized Uptake Value
Aorta
|
1.75 SUV
Standard Deviation 0.34
|
0.88 SUV
Standard Deviation 0.17
|
|
Standardized Uptake Value
Liver
|
2.49 SUV
Standard Deviation 0.44
|
1.02 SUV
Standard Deviation 0.19
|
|
Standardized Uptake Value
Spleen
|
2.15 SUV
Standard Deviation 0.40
|
0.83 SUV
Standard Deviation 0.15
|
|
Standardized Uptake Value
Kidneys
|
3.65 SUV
Standard Deviation 1.85
|
1.45 SUV
Standard Deviation 0.23
|
|
Standardized Uptake Value
Bone Marrow
|
2.51 SUV
Standard Deviation 0.44
|
0.73 SUV
Standard Deviation 0.15
|
|
Standardized Uptake Value
Skeletal Muscles
|
0.70 SUV
Standard Deviation 0.19
|
0.37 SUV
Standard Deviation 0.06
|
|
Standardized Uptake Value
Subcutaneous Fat
|
0.19 SUV
Standard Deviation 0.05
|
0.19 SUV
Standard Deviation 0.04
|
|
Standardized Uptake Value
Whole Brain
|
9.88 SUV
Standard Deviation 2.63
|
4.95 SUV
Standard Deviation 1.36
|
|
Standardized Uptake Value
Myocardium
|
10.73 SUV
Standard Deviation 4.92
|
1.20 SUV
Standard Deviation 0.80
|
PRIMARY outcome
Timeframe: approximatively 3 hoursTo obtain preliminary data to understand whether intravenous iodinated contrast agent produce a significant change in quantification of FDG uptake levels. Time/activity curves will be generated.
Outcome measures
| Measure |
Delayed Imaging Acquisition
n=15 Participants
10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
EXPLORER PET/CT: Intervention: PET/CT using different protocols
|
Arm 2
n=15 Participants
Average SUV mean at 90 minutes
|
|---|---|---|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Subcutaneous Fat
|
0.16 SUV
Standard Deviation 0.05
|
0.07 SUV
Standard Deviation 0.02
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Aorta
|
1.18 SUV
Standard Deviation 0.30
|
0.39 SUV
Standard Deviation 0.08
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Lungs
|
0.52 SUV
Standard Deviation 0.53
|
0.15 SUV
Standard Deviation 0.04
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Liver
|
2.11 SUV
Standard Deviation 0.42
|
0.50 SUV
Standard Deviation 0.10
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Spleen
|
2.09 SUV
Standard Deviation 0.41
|
0.43 SUV
Standard Deviation 0.08
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Kidneys
|
3.30 SUV
Standard Deviation 1.34
|
0.66 SUV
Standard Deviation 0.12
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Bone Marrow
|
2.92 SUV
Standard Deviation 0.56
|
0.44 SUV
Standard Deviation 0.09
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Skeletal Muscles
|
0.82 SUV
Standard Deviation 0.21
|
0.21 SUV
Standard Deviation 0.04
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Whole Brain
|
10.39 SUV
Standard Deviation 3.02
|
2.97 SUV
Standard Deviation 0.86
|
|
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UM
Myocardium
|
11.60 SUV
Standard Deviation 5.92
|
0.68 SUV
Standard Deviation 0.59
|
Adverse Events
Delayed Imaging Acquisition
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Low FDG Dose Imaging
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Comparison PET Images Reconstructed Using CT-based Attenuation
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place